1999 – Senzime is founded with the business idea of developing patient-oriented systems for measuring life-critical substances.
2001 – The Crafoord family, represented by Adam Dahlberg, invests in the company
2004 – The first prototype is completed: CliniSenz – a blood glucose analyzer for post-operative and continuous monitoring of patients in a hospital environment.
2007 – Senzime is admitted to trading on Aktietorget
2011 – Patent obtained for CliniSenz®.
2015 – Senzime acquires MD Biomedical AB, the developer of OnZurf®Probe, a new generation of microdialysis catheters
2016 – Senzime acquires Acacia Designs B.V. thereby obtaining TetraGraph®, broadening the product range to include solutions for patients undergoing anaesthesia
2016 – Licensing agreement with Fukuda Denshi in Japan
2017 – Senzime listed on Nasdaq Stockholm First North Growth Market
2019 – Senzime receives marketing approval in the US, Japan and South Korea, allowing it to market and sell its products in these markets
2020 – OnZurf® is out-licensed for the European market
2020 – Senzime establishes a subsidiary in the US, Senzime Inc., builds a sales organisation and receives a breakthrough order from a US university hospital
2021 – Senzime establishes a subsidiary in Germany, receives first breakthrough order from German university hospital
2021 – Senzime applies for listing on Nasdaq Stockholm’s main list